Trials / Completed
CompletedNCT00107094
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer
An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
In this trial, the safety of combination treatment of Adriamycin plus cyclophosphamide followed by Abraxane as adjuvant therapy will be evaluated in patients with limited stage breast cancer.
Detailed description
This is an open-label, pilot study to evaluate the safety of Adriamycin and cyclophosphamide (AC) administered every 2 weeks for 4 cycles followed by Abraxane administered every 2 weeks for 4 cycles as adjuvant therapy for patients with limited stage breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abraxane |
Timeline
- Start date
- 2005-03-01
- First posted
- 2005-04-06
- Last updated
- 2007-07-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00107094. Inclusion in this directory is not an endorsement.